AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/07/24

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a firesi...

2024-05-06 14:15:24 ET Summary Eighteen new analysts joined in April. This article features summaries of their initial publications and recommendations, covering a wide range of companies across sectors including finance, technology, healthcare, and energy. Take a look to find...

2024-05-02 16:49:49 ET Summary AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter. AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 whether in AUPH's hands, or externally if the drug ...

2024-05-02 12:03:11 ET Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Conference Call May 02, 2024 08:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer Joe Mi...

2024-05-02 10:45:03 ET Sabre Corp (SABR) SABR is trading UP for the last 5 days, and it at trading at $2.97 with volume of 2,856,606 and a one day change of $0.07 (2.42%). Sabre Corp has a 52-week low of 1.81 and a 52-week high of $5.77. The business's 50-day moving average price is...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-05-02 06:09:37 ET More on Aurinia Pharma Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024 Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed Aurinia Pharm...

Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent growth in LUPKYNIS ® (voclosporin) sales Rapidly com...

2024-05-01 11:43:59 ET More on Aurinia Pharma Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024 Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed Aurinia gains...

In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innov...